Epigenetix
- Biotech or pharma, therapeutic R&D
Clinical stage cancer company with first-in-class multi-targeted oral small molecule drug. Sgns of efficacy in Myelofibrosis with a JAK combination including spleen volume reduction and symptom improvement. Also signs in AML where we are expanding into combinations with Menin inhibitors and BC-2 inhibitors where there is strong rational and preclinical evidence. . In NUT carcinoma we have a patient that has been treated for 18 months showing long term safety and durability of response.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}